4basebio PLC
88Q
Company Profile
Business description
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Contact
25 Norman Way
Over
CambridgeCB24 5QE
GBRT: +44 1223967943
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
110
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
We maintain our fair value estimate for TSMC stock.
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Trying to make sense of a share caught up in irrational exuberance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,301.71 | 39.01 | 0.47% |
| DAX 40 | 24,274.33 | 119.86 | 0.50% |
| Dow JONES (US) | 48,578.72 | 115.00 | 0.24% |
| FTSE 100 | 10,567.61 | 22.38 | -0.21% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,102.70 | 86.69 | 0.36% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,041.28 | 18.33 | 0.26% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |